Under the oncology category, the top-prize winning abstract EAU 10-13 march (Milano, IT) A1163 Proteomic profiling of muscle-invasive bladder cancer treated with neoadjuvant chemotherapy described four pre-NAC and two post-NAC proteomic clusters with distinct biology and survival outcomes, alongside novel prognostic biomarkers. The future work for this research will include the validation of these clusters by IHC (immunohistochemistry) in larger independent MIBC cohorts. A non-NAC cohort using pre-NAC tissue will be used to confirm the prognostic versus predictive relevance of these findings.
Discussant Prof. Lars Dyrskjøt (DK) stated, “Hopefully in the future, we can create a combination of tissue analysis and liquid biopsy analysis, and then profile the different genomics, transcriptomics, proteomics, and metabolomics layers to generate models that broaden our understanding of the disease development but also make us more capable in identifying novel biomarkers. This study here is an important addition to understanding the complexity of MIBC.”
The second prize was given to A0890 The Stockholm3 prostate cancer screening trial (STHLM3): An interim analysis of mortality results after 6.5 years of follow-up which concluded that the results cautiously suggest a potential effect on reducing prostate cancer mortality by a single intensive screening intervention using PSA and Stockholm3 in combination to the cost of increasing prostate cancer incidence. Longer-term follow-up is needed and is underway.
Discussant Prof. Albers (DE) stated that data has shown that mortality difference using Stockholm3 as a screening tool is favourable, and that PSA > 3 is confirmed as a good screening cut-off. He added that the acceptance of STHLM3 in a population setting remains unclear and the different components of STHLM3 needs to be quantified. According to Prof. Albers, the role of genotyping as a reflex test and the cost effectiveness of MRI (magnetic resonance imaging) versus STHLM3 need to explored.
13 march 2023